PDS01ADC Shows 9.6-Month Median PFS in Late-Stage Prostate Cancer Trial
Event summary
- PDS01ADC achieved median PFS of 9.6 months in NCI-led Phase 2 study for 3rd-line mCRPC patients.
- 6 of 16 patients showed >50% PSA decline in combination therapy with docetaxel.
- Results presented at AACR Special Conference on Prostate Cancer (Jan 20-22, 2026).
- PDS01ADC targets necrotic DNA in tumors to deliver IL-12, enhancing immune response.
The big picture
PDS Biotech's Phase 2 results position PDS01ADC as a potential game-changer in late-stage prostate cancer treatment, particularly for patients with limited remaining options. The study's success highlights the growing importance of targeted immunocytokines in oncology, where combination therapies are increasingly becoming the standard of care. The company's ability to secure NCI partnership and present at AACR underscores the clinical and regulatory credibility of its approach.
What we're watching
- Clinical Validation
- Whether these Phase 2 results can translate into successful Phase 3 outcomes for PDS01ADC.
- Combination Therapy
- How the synergy between PDS01ADC and docetaxel will be leveraged in future trials.
- Pipeline Progression
- The pace at which PDS Biotech can advance its immuno-oncology pipeline beyond prostate cancer.
Related topics